Argenica Therapeutics Ltd
ASX:AGN
Argenica Therapeutics Ltd
Net Income (Common)
Argenica Therapeutics Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Net Income (Common)
-AU$5.5m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Income (Common)
-AU$174.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Income (Common)
AU$142m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Net Income (Common)
-AU$39.3m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-42%
|
|
|
Probiotec Ltd
ASX:PBP
|
Net Income (Common)
AU$8.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
21%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Net Income (Common)
AU$8.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
23%
|
CAGR 10-Years
2%
|
|
Argenica Therapeutics Ltd
Glance View
Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.
See Also
What is Argenica Therapeutics Ltd's Net Income (Common)?
Net Income (Common)
-5.5m
AUD
Based on the financial report for Jun 30, 2024, Argenica Therapeutics Ltd's Net Income (Common) amounts to -5.5m AUD.
What is Argenica Therapeutics Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-75%
Over the last year, the Net Income (Common) growth was -14%. The average annual Net Income (Common) growth rates for Argenica Therapeutics Ltd have been -75% over the past three years .
You don't have any saved screeners yet